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A PET tracer for tumor imaging, 3-18F-L-a-methyl-tyrosine ([18F]FAMT), has advantages of high cancer-
speciﬁcity and low physiological background. In clinical studies, FAMT-PET has been proved useful for
the detection of malignant tumors and their differentiation from inﬂammation and benign lesions. The
tumor speciﬁc uptake of FAMT is due to its high-selectivity to cancer-type amino acid transporter LAT1
among amino acid transporters. In [18F]FAMT PET, kidney is the only organ that shows high physiological
background. To reveal transporters involved in renal accumulation of FAMT, we have examined [14C]
FAMT uptake on the organic ion transporters responsible for the uptake into tubular epithelial cells. We
have found that OAT1, OAT10 and OCTN2 transport [14C]FAMT. The [14C]FAMT uptake was inhibited by
probenecid, furosemide and ethacrynic acid, consistent with the properties of the transporters. The
amino acid uptake inhibitor, 2-amino-2-norbornanecarboxylic acid (BCH), also inhibited the [14C]FAMT
uptake, whereas OCTN2-mediated [14C]FAMT uptake was Naþ-dependent. We propose that FAMT uptake
by OAT1, OAT10 and OCTN2 into tubular epithelial cells could contribute to the renal accumulation of
FAMT. The results from this study would provide clues to the treatments to reduce renal background and
enhance tumor uptake as well as to designing PET tracers with less renal accumulation.
© 2016 Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In positron emission tomography (PET) for tumor imaging, a
glucose analog, 2-18F-ﬂuoro-2-deoxy-D-glucose ([18F]FDG), hasmost
commonly been used as a PET tracer (1). Although [18F]FDG PET has
been used successfully for the clinical diagnosis ofmalignant tumors,
it sometimes suffers from false-positive ﬁndings in inﬂammatory
tissues and benign lesions and high physiological backgrounds
particularly in brain (2). It is due to the upregulation or high level ofm Pharmacology, Graduate
Suita, Osaka 565-0871, Japan.
p (Y. Kanai).
rmacological Society.
r B.V. on behalf of Japanese Pharmexpression of glucose transporters responsible for cellular uptake of
FDG in non-tumor tissues (2e4). Amino acid PET tracers have, thus,
been developed to overcome such disadvantages of [18F]FDG PET,
because they generally exhibit more tumor-selective properties (5).
For example, L-[11C-methyl]methionine ([11C]MET) and O-(2-[18F]
ﬂuoroethyl)-L-tyrosine ([18F]FET) (Supplemental Fig. 1) have been
shown to be less accumulated in brain and inﬂammatory lesions
compared with [18F]FDG (5), although they still exhibit some extent
of false-positives and physiological backgrounds in PET (6, 7).
In single photon emission computed tomography (SPECT), an
amino acid tracer 3-123I-L-a-methyl-tyrosine ([123I]IMT)
(Supplemental Fig. 1) has been used for tumor imaging (5). [123I]IMT
accumulates in malignant tumors with less false positives and with
low background in brain (5). Based on such high tumor speciﬁcity of
[123I]IMT, 3-18F-L-a-methyl-tyrosine ([18F]FAMT) (Supplemental Fig.1)
has been developed as a PET tracer for tumor imaging by substitutingacological Society. This is an open access article under the CC BY-NC-ND license
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that [18F]FAMT accumulates speciﬁcally in malignant tumors (9e16).
[18F]FAMT-PET has been proved useful for the prediction of prognosis
and for the differentiation of malignant tumors from inﬂammation
and benign lesions (9e16). In the previous study, we showed that
FAMT is speciﬁcally transportedbycancer-type aminoacid transporter
L-typeaminoacid transporter1 (LAT1, SLC7A5),whichexplains tumor-
speciﬁc accumulation of [18F]FAMT in PET (17). LAT1 is a Naþ-inde-
pendent amino acid transportermediating the uptake of large neutral
amino acids including aromatic and branched-chain amino acids (18,Fig. 1. [14C]FAMT transport by organic anion transporters. The uptake of 50 mM [14C]FAM
(A), OAT3 (B) and OAT10 (D). The uptake of 50 mM [14C]FAMT (FAMT) and a typical substrat
typical substrate [3H]estrone-3-sulfate (ES) was measured for OAT4 (C). The uptake was me
(“þ”) in ND96 buffer. The uptake rate was expressed as mean ± SEM (n ¼ 6e10). *, p < 0.019). It is predominantly expressed in primary tumors of various tis-
sue origins and their metastatic lesions except some non-tumor cells
(20, 21). We showed that a-methyl moiety of FAMT is responsible for
its preference for LAT1 (17,22e24). In fact, the accumulation of [18F]
FAMT in PET is well correlated with the level of LAT1 expression in
various tumors (11, 12, 14, 16).
In [18F]FAMT PET, kidney is the only organ that shows high
physiological uptake of [18F]FAMT, limiting its use for the diagnosis
of renal carcinoma (9, 10, 13, 16, 25). Renal accumulation of SPECT
tracer [123I]IMT with the FAMT-related structure (SupplementalT (FAMT) and a typical substrate [14C]p-aminohippurate (PAH) was measured for OAT1
e [14C]urate was measured for URAT1 (E). The uptake of 5 mM [14C]FAMT (FAMT) and a
asured for 30 min on the control oocytes (“”) and the oocytes expressing transporter
5; n.s., not signiﬁcant.
Fig. 2. [14C]FAMT transport by organic cation transporters. The uptake of 50 mM
[14C]FAMT (FAMT) and a typical substrate [14C]tetraethylammonium (TEA) was
measured for 30 min on the control oocytes (“”) and the oocytes expressing OCT1 (A)
or OCT2 (B) (“þ”) in ND96 buffer. The uptake rate was expressed as mean ± SEM
(n ¼ 5e10). *, p < 0.05; n.s., not signiﬁcant.
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aminohippurate (26, 27), suggesting it to be a transporter-mediated
process (28). Furthermore, probenecid, furosemide and ethacrynic
acid, which interact with organic anion transporters (29e31),
reduced tubular secretion of [125I]IMT in mice (28). Therefore, in
the present study, in order to reveal transporters involved in renal
accumulation of FAMT in PET, we have examined the transport of
14C-labeled FAMT on the organic ion transporters responsible for
the uptake of organic solutes into tubular epithelial cells in kidney.
2. Materials and methods
2.1. Radiolabeled chemicals
[14C]FAMT was synthesized by Sekisui Medical (Tokyo, Japan) to
obtain high speciﬁc radioactivity by BücherereStrecker reaction
using 3-ﬂuoro-4-methoxyphenylacetone (NARD Institute, Ltd.,
Amagasaki, Japan) as a starting material (32). [14C]FAMT was
identified by 1H nuclear magnetic resonance analysis (AV400M,
Bruker Biospin), high-performance liquid chromatography (Agilent
1200) and mass spectrometry (LTQ XL, Thermo Fisher Scientiﬁc)
(17). The purity of the [14C]FAMT was determined to be 99% by
high-performance liquid chromatography. Its speciﬁc activity was
1.77 GBq/mmol.
[14C]p-aminohippurate (2.04 GBq/mmol), [14C]urate (2.04 GBq/
mmol) and [14C]tetraethylammonium (2.04 GBq/mmol) were pur-
chased from American Radiolabeled Chemicals (St. Louis, MO). [3H]
estrone-3-sulfate (1.665 TBq/mmol) was obtained from Perki-
nElmer (Boston, MA).
2.2. Chemicals
p-Aminohippurate, estrone-3-sulfate, tetraethylammonium and
2-amino-2-norbornanecarboxylic acid (BCH) were purchased from
Sigma-Aldrich (St. Louis, MO). Non-radiolabeled FAMT was pur-
chased from NARD Institute, Ltd. (Amagasaki, Japan) (17). Other
general chemicals were obtained from Wako (Osaka, Japan).
2.3. cDNAs and complementary RNA (cRNA) synthesis
cDNAs for human transporters used in this study were listed in
Supplemental Table 1. In vitro transcription was performed to
synthesize polyadenylated cRNAs from linearized plasmids using
mMESSAGE mMACHINE® Kit and Poly (A) Tailing Kit (Ambion,
Austin, TX) following themanufacturer's protocol. cRNAswere then
puriﬁed with MEGAclear™ Kit (Ambion, Austin, TX). Plasmid vec-
tors, restriction enzyme sites for subcloning, enzymes for lineari-
zation and RNA polymerases used for cRNA synthesis were
described in Supplemental Table 1.
2.4. Xenopus laevis oocyte expression and uptake measurements
Defolliculated oocytes were injected with polyadenylated cRNA
(25 ng/oocyte). The oocytes were, then, incubated at 18 C in Barth's
saline (18, 33). Uptakemeasurementswere performed2e4 days after
injectionof cRNAaspreviously described (18, 33). In brief, theoocytes
were incubated at room temperature with 500 ml uptake solution
containing 7.4e148 kBq of 14C-labeled compounds or 166.5 kBq of
[3H]estrone-3-sulfate at the designated concentration for the time
periods indicated.ND96buffer (96mMNaCl, 2mMKCl,1.8mMCaCl2,
1mMMgCl2, 5mMHEPES, pH7.5)wasusedas theuptake solution for
Naþ-dependent transport. For Naþ-free uptake solution, NaCl was
replaced by choline-Cl. The oocytes were then washed with ice-cold
uptake solution, lysed in 10% sodium dodecyl sulfate. The radioac-
tivity was determined by liquid scintillation counting.Functional expression of each transporter in Xenopus oocytes
was conﬁrmed by measurement of the uptake of its typical sub-
strate as described in the legends to ﬁgures. To examine the
dependence of the transport on substrate concentrations, the up-
take of [14C]FAMT was measured in the oocytes expressing OAT10
at varied concentration of FAMT. Transport rate at each concen-
tration was obtained by subtracting the uptake rate of control oo-
cytes without cRNA injection from that of the oocytes expressing
OAT10. The transport rate was plotted against FAMT concentration
and ﬁtted to a MichaeliseMenten curve to obtain Michaelis con-
stant (Km) andmaximal transport rate (Vmax) using enzyme kinetics
module of SigmaPlot 12.5 (Systat Software, San Jose, CA).
EadieeHofstee plot was also obtained using enzyme kinetics
module of SigmaPlot 12.5 (Systat Software, San Jose, CA). In the
inhibition experiments, the uptake of 5 mM [14C]FAMT were
measured in the presence of inhibitors (500 mM for probenecid,
furosemide and ethacrynic acid; 0.1, 0.5 and 5 mM for BCH).
For transport measurements, 5 to 13 oocytes were used for each
measurement. Each data in the ﬁgures represents the mean ± SEM
To conﬁrm the reproducibility of the results, three separate ex-
periments using different batches of oocytes were performed.
Statistical differences were determined using the Student's un-
paired t-test. Differences were considered signiﬁcant at p < 0.05.
Table 1
Transport of [14C]FAMT by organic ion transporters in kidney.
Organic ion transporter Gene [14C]FAMT
Organic anion OAT1 SLC22A6 þ1
OAT3 SLC22A8 e
OAT4 SLC22A11 e
OAT10 SLC22A13 þ
URAT1 SLC22A12 e
Organic cation OCT1 SLC22A1 e
OCT2 SLC22A2 e
Zwitterion OCTN1 SLC22A4 e
OCTN2 SLC22A5 þ
1 “þ” indicates that [14C]FAMT is transported by the designated transporter,
whereas “e” indicates that [14C]FAMT is not transported.
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3.1. OAT1, OAT10 and OCTN2 mediate [14C]FAMT transport
In order to reveal the transporters involved in renal accumula-
tion of FAMT in PET, we examined organic ion transporters involved
in the uptake into renal tubular epithelial cells (Supplemental
Fig. 2): organic anion transporters OAT1, OAT3, OAT4, OAT10 and
URAT1; organic cation transporters OCT1 and OCT2; zwitterion
transporters OCTN1 and OCTN2 (Supplemental Table 1) (29e31).
We found that OAT1 and OAT10 transported [14C]FAMT among
organic anion transporters (Fig. 1A, D), whereas OAT3, OAT4 and
URAT1 did not transport [14C]FAMT (Fig. 1B, C, EE). Organic cation
transporters OCT1 and OCT2 did not transport [14C]FAMT (Fig. 2A,
B). In zwitterion transporters, OCTN2 transported [14C]FAMT,
whereas OCTN1 did not (Fig. 3A, B). The results on the organic ion
transporters are summarized in Table 1.
3.2. Concentration-dependent [14C]FAMT transport by OAT10
Because the expression of OAT10 in oocytes resulted in a
prominent increase of [14C]FAMT uptake (Fig. 1D), concentration-
dependence of [14C]FAMT transport was able to be determined.
As shown in Fig. 4, OAT10-mediated [14C]FAMT transport wasFig. 3. [14C]FAMT transport by zwitterion transporters. The uptake of 50 mM [14C]
FAMT (FAMT) and a typical substrate [14C]tetraethylammonium (TEA) was measured
for 30 min on the control oocytes (“”) and the oocytes expressing OCTN1 (A) or
OCTN2 (B) (“þ”) in ND96 buffer. The uptake rate was expressed as mean ± SEM
(n ¼ 8e13). *, p < 0.05; n.s., not signiﬁcant.saturable and followed MichaeliseMenten kinetics. Its Km and Vmax
values were 351.0 ± 62.0 mM and 3.9 ± 0.3 pmol/oocyte/min,
respectively (Fig. 4).
3.3. Properties of [14C]FAMT transport mediated by OAT1, OAT10
and OCTN2
The [14C]FAMT transports by OAT1, OAT10 and OCTN2 were
examined in terms of the interaction with probenecid, furosemide
and ethacrynic acid which were reported to affect renal handling of
SPECT tracer [123I]IMT with the FAMT-related structure (28). As
shown in Fig. 5A and B, the transports of [14C]FAMT (5 mM) medi-
ated by OAT1 and OAT10 were signiﬁcantly inhibited by probene-
cid, furosemide and ethacrynic acid (500 mM). The [14C]FAMT
transport mediated by OCTN2 was inhibited signiﬁcantly by pro-
benecid and ethacrynic acid (Fig. 5C).
Because it was once suggested that IMT uptake was partly
mediated by Naþ-dependent and BCH-inhibitable component(s)
(28), we examined the effect of BCH (Supplemental Fig. 1) and Naþ
on the [14C]FAMT transport mediated by OAT1, OAT10 and OCTN2.
As shown in Fig. 6B, the transport of [14C]FAMT (5 mM)mediated by
OAT10 was inhibited by BCH in a concentration dependent manner.
The [14C]FAMT uptakes by OAT1 and OCTN2 were also inhibited by
BCH at 5 mM (Fig. 6A, C). Furthermore, the comparison of [14C]
FAMT transport in the presence and absence of Naþ indicated that
OCTN2-mediated [14C]FAMT transport is highly dependent on Naþ,
whereas [14C]FAMT transports by OAT1 and OAT10 were Naþ-in-
dependent (Fig. 7).Fig. 4. Concentration dependence of [14C]FAMT transport. Concentration depen-
dence of [14C]FAMT transport mediated by OAT10 was determined. OAT10-mediated
[14C]FAMT transport at 3, 10, 30, 100, 300, and 500 mM was measured for 30 min in
ND96 buffer. Transport rate was expressed as mean ± SEM (n ¼ 7e9) and ﬁtted to
MichaeliseMenten curve to obtain the kinetic parameters. Inset, EadieeHofstee plot of
OAT10-mediated [14C]FAMT transport.
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In this study, we have revealed that FAMT, an aromatic amino
acid PET tracer, is transported by OAT1, OAT10 and OCTN2 among
organic ion transporters involved in the uptake into renal tubular
epithelial cells (Figs. 1 and 3). The uptake was inhibited by organic
anions such as probenecid, furosemide and ethacrynic acid (Fig. 5).
Interestingly, it was also inhibited by BCH, an amino acid trans-
porter inhibitor (Fig. 6). OCTN2-mediated FAMT uptake was
dependent on Naþ as expected from the properties of OCTN2-
mediated transport (Fig. 7). In the uptake assay, we used a Xen-
opus oocyte expression system and not the stably expressing cell
lines generally used for organic ion transporters, because [14C]Fig. 5. Inhibition of [14C]FAMT transport by probenecid, furosemide and ethacrynic acid
presence of 500 mM inhibitor (probenecid, furosemide or ethacrynic acid) for 30 min on th
OCTN2 (C) (ﬁlled columns) in ND96 buffer. Right panels: the rate of transport mediated by
control oocytes from that of the oocytes expressing each transporter shown in the left panel
compared with [14C]FAMT transport in the absence of inhibitors (“”); n.s., not signiﬁcant.FAMT is transported by LAT1 expressed in cultured cell lines in
general, which generates high background uptake (22, 23).
In [18F]FAMT PET, the remarkable physiological uptake is found
only in kidney (9, 10, 13, 16, 25). In kidney, non-protein bound low
molecular weight compounds including amino acids are ﬁltered
through glomerulus and reabsorbed by the transporters in the
apical membrane of renal proximal tubules if the compounds are
the substrates of the transporters. On the other hand, some frac-
tions of organic ions in blood are taken up by the transporters in
basolateral membrane of tubular epithelial cells and excreted into
urine via the transporters of apical membrane (30). If PET or SPECT
tracers are the substrates of such transporters in kidney, they could
be taken up by the transporters in apical or basolateral membrane. Left panels: the uptake of 5 mM [14C]FAMT was measured in the absence (“”) or the
e control oocytes (gray columns) and the oocytes expressing OAT1 (A), OAT10 (B) or
OAT1 (A), OAT10 (B) or OCTN2 (C) was obtained by subtracting the uptake rate of the
s. The uptake and transport rate were expressed as mean ± SEM (n ¼ 6e10). *, p < 0.05
Fig. 6. Inhibition of [14C]FAMT transport by BCH. Left panels: the uptake of 5 mM [14C]FAMT was measured in the presence (BCH (þ)) or the absence (BCH ()) of 0.1, 0.5 and 5 mM
BCH for 30 min on the control oocytes (“”) and the oocytes expressing OAT1 (A), OAT10 (B) or OCTN2 (C) (“þ”) in ND96 buffer. Right panels: the rate of transport mediated by OAT1
(A), OAT10 (B) or OCTN2 (C) was obtained by subtracting the uptake rate of the control oocytes from that of the oocytes expressing each transporter shown in the left panels. The
uptake and transport rate were expressed as mean ± SEM (n ¼ 5e10). OAT10-mediated [14C]FAMT transport was signiﬁcantly inhibited by 0.5 and 5 mM BCH, whereas the
transports of [14C]FAMT by OAT1 and OCTN2 were inhibited signiﬁcantly by 5 mM BCH (*p < 0.05). n.s., not signiﬁcant.
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background in the imaging. For example, SPECT tracer [123I]IMT
with the FAMT-related structure has been proposed to be accu-
mulated in kidney via transporter-mediated processes (28).
Because [18F]FAMT was not transported by amino acid transporters
responsible for renal handling of aromatic amino acids such as
B0AT1, b0,þ, LAT2 and TAT1 (34) (Supplemental Fig. 3), we examined
organic ion transporters involved in the uptake into epithelial cellsof renal proximal tubules to reveal the mechanisms of renal accu-
mulation of [18F]FAMT in PET. This is based on the reports that some
organic ion transporters accept amino acids: OAT1 and OAT3 are
inhibited by an aromatic amino acid 3-hydroxykynurenine (35);
OCTN2 transports L-lysine (36).
In the basolateral membrane of renal proximal tubules, organic
anions are taken up by tubular epithelial cells mainly via OAT1 and
OAT3, whereas organic cations are taken up via OCT1 and OCT2
Fig. 7. Sodium dependence of [14C]FAMT transport. Left panels: the uptake of 5 mM [14C]FAMT was measured for 30 min in the presence (Naþ(þ)) or the absence (Naþ()) of
sodium on the control oocytes (“”) and the oocytes expressing OAT1 (A), OAT10 (B) or OCTN2 (C). Right panels: the rate of transport mediated by OAT1 (A), OAT10 (B) or OCTN2 (C)
were obtained by subtracting the uptake rate of the control oocytes from that of the oocytes expressing each transporter shown in the left panels. The uptake and transport rate
were expressed as mean ± SEM (n ¼ 5e10). [14C]FAMT transport by OAT1 and OAT10 was not affected by sodium (n.s.), whereas the transport mediated by OCTN2 signiﬁcantly
decreased in the absence of sodium (*p < 0.05).
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organic anions are reabsorbed from luminal ﬂuid by OAT4, OAT10
and URAT1, whereas OCTN1 and OCTN2 are responsible for the
luminal uptake of zwitterions and organic cations (Supplemental
Fig. 2) (22, 29, 30, 37). Among the transporters involved in the
uptake of organic ions into tubular epithelial cells, we showed in
the present study that OAT1, OAT10 and OCTN2 transport [14C]
FAMT (Table 1). OAT1 is localized in S2 segment, the middle portion
of proximal tubules, and mediates the entry of organic anions
including anionic drugs into the epithelial cells from basolateral
side (29, 30, 38). The differential interaction of FAMTwith OAT1 and
OAT3 we found in the present study is intriguing, which would
contribute to the understanding of the substrate recognition
mechanisms in such closely-related transporters by adding a
distinct compound to the substrate list of OAT1 and OAT3 (37).
OAT10 mainly reabsorbs endogenous organic anions including
urate and nicotinate from the apical side (29, 30, 39). OAT10
exhibited the prominent uptake of [14C]FAMT (Fig. 1D), although
the afﬁnity to FAMT was lower than that for the endogenous sub-
strates (Fig. 4) (39). OCTN2 is responsible for the reabsorption of L-
carnitine and cationic substrates (29, 30). It is, thus, suggested that
OAT1mediates FAMT uptake into tubular epithelial cells from blood
side whereas OAT10 and OCTN2 mediate the uptake from urinary
side, all of which could contribute to the renal accumulation of [18F]
FAMT in PET.
As for IMT, it was reported in mice that [125I]IMT accumulates
mainly in S2-like region of renal cortex and its accumulation is
highly suppressed by probenecid and p-aminohippurate (26, 27)
that inhibit organic anion transporters including OAT1 and OAT10
(29, 38, 39). Furthermore, probenecid, furosemide and ethacrynic
acid, all of which inhibit organic anion transporters (29, 30),
reduced tubular secretion of [125I]IMT into urine in mice, suggest-
ing that signiﬁcant portion of IMT is taken up from blood side by
the organic anion transporters of basolateral membrane and
excreted into urine through the apical membrane (28). In the
course of such transcellular transport, IMT would accumulate in
renal tubules. The accumulation of [125I]IMT in S2-like region let us
speculate that OAT1 present in S2 segment (38) at least contributes
to the renal accumulation of [125I]IMT, while, at the moment, the
detailed tubular distribution is not determined for OAT10 and
OCTN2. As shown in Fig. 5, [14C]FAMT transports by OAT1, OAT10
and OCTN2 are mostly inhibited by probenecid, furosemide and
ethacrynic acid, suggesting that particularly probenecid with rela-
tively higher plasma concentration at clinical dosage (40) could
suppress the renal accumulation of [18F]FAMT in PET when
administered at appropriate doses.
It was furthermore reported for IMT that, in cultured human
renal proximal tubule epithelial cells in vitro, the small portion of
[125I]IMT uptake is inhibited by BCH, an inhibitor of amino acid
transport systems L, B0 and B0,þ (34), in a Naþ-dependent manner
(28). Based on this, the contribution of Naþ-dependent BCH-
inhibitable system B0 was once proposed (28). While [14C]FAMT
was not transported by B0AT1, a system B0 transporter responsible
for renal reabsorption of neutral amino acids (Supplemental Fig. 3),
we found that [14C]FAMT uptakes by OAT1, OAT10 and OCTN2 are
inhibited by BCH (Fig. 6) although the afﬁnity of OATs to BCH seems
lower than that of amino acid transporters (23). The OCTN2-
mediated [14C]FAMT uptake was dependent on Naþ as expected
from the properties of OCTN2-mediated transport (41) (Fig. 7).
Therefore, Naþ-dependent BCH-inhibitable component is not
necessarily attributed to amino acid transport system B0 but OCTN2
can be an alternative candidate.
Interestingly, the tumor uptake of [125I]IMT was reported to be
enhanced by probenecid (27). It is probably because probenecid
prevents the urinary loss of [125I]IMT and maintains its blood level,although probenecid inhibits transporters for both reabsorption
and excretion of organic anions (27, 30). This suggests that kidney
excretes IMT mainly through transcellular transport from blood to
urine at the proximal tubule (Supplemental Fig. 2). The action of
probenecid on the organic anion transporters in the basolateral
membrane is supposed to be responsible for this effect, consistent
with the observation that the administration of probenecid
reduced tubular secretion of [125I]IMT into urine in mice (28).
Suppose that FAMT with a quite similar structure to IMT behaves
similarly in terms of interaction with tubular transporters, it would
be expected that the appropriate dose of probenecid or other high-
afﬁnity OAT inhibitors might be used to enhance the tumor uptake
as well as to reduce renal background of [18F]FAMT in PET similar to
IMT (27).
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